ArticleCancer management and research2019
Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC.
Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 46 citations in OpenAlex.
- Research on EBV-miR-BART17-5p targeted Inhibition of ARID1A expression to regulate nasopharyngeal carcinoma dedifferentiation.Cancer cell international · 2026Article
- Epigenetics: the master switch of nasopharyngeal carcinoma invasion and metastasis.Frontiers in immunology · 2026Review
- Establishment of novel cholangiocarcinoma cell lines with ARID1A deficiency and preclinical validation of synthetic lethality therapies.Scientific reports · 2025Article
- The role and mechanism of ARID1A in immunotherapy of gastric cancer.Clinical and experimental medicine · 2025Article
- Targeting the FOXA1/BMI1 axis to overcome chemoresistance and suppress tumor progression in nasopharyngeal carcinoma.Cell death discovery · 2025Article
- Targeting on the PI3K/mTOR: a potential treatment strategy for clear cell ovarian carcinoma.Cancer chemotherapy and pharmacology · 2025Article
- ARID1A Governs Genomic Stability and Proliferation in SCLC via c-MYC/PARP1 Suppression Driving Vulnerability to BET Inhibitors.Research (Washington, D.C.) · 2025Article
- Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma.CNS neuroscience & therapeutics · 2024Article
- Explore the alterations of downstream molecular pathways caused by ARID1A mutation/knockout in human endometrial cancer cells.Journal of cancer research and clinical oncology · 2023Article
- ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.Journal of cancer research and clinical oncology · 2023Article
- Feature Reviews of the Molecular Mechanisms of Nasopharyngeal Carcinoma.Biomedicines · 2023Review
- PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.Frontiers in oncology · 2023Article
- Zinc deficiency is associated with the development of ovarian endometrial cysts.American journal of cancer research · 2023Article
- Mutational signatures are markers of drug sensitivity of cancer cells.Nature communications · 2022Article
- SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner.Journal of translational medicine · 2022Article
- Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8The Journal of pathology · 2022Article
- Case report: Unique FLT4 variants associated with differential response to anlotinib in angiosarcoma.Frontiers in oncology · 2022Article
- Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value.American journal of translational research · 2022Review
- Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.PLoS genetics · 2021Article
- Histone deacetylase HDAC2 silencing prevents endometriosis by activating the HNF4A/ARID1A axis.Journal of cellular and molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.